newsfilter
← Latest News
GlobeNewswire·

Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024 Longer-term cosibelimab results demonstrate substantial